Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

被引：63

作者：

Luke, Jason J. ^{[1
]}

Hodi, F. Stephen

机构：

[1] Dana Farber Canc Inst, Melanoma Dis Ctr, Boston, MA 02215 USA

来源：

ONCOLOGIST | 2013年 / 18卷 / 06期

关键词：

CTLA-4; Immunotherapy; BRAF; MEK; Resistance; Biomarker; MEK INHIBITOR TRAMETINIB; UNRESECTABLE STAGE-III; METASTATIC MELANOMA; OPEN-LABEL; PHASE-II; COMBINATION IMMUNOTHERAPY; SELECTIVE INHIBITOR; ACQUIRED-RESISTANCE; ANTIGEN-4; ANTIBODY; IMPROVED SURVIVAL;

D O I：

10.1634/theoncologist.2012-0391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with ipilimumab, and targeting of BRAF(V600), with vemurafenib or dabrafenib, as well as MEK, with trametinib, have been paradigm changing both for melanoma clinical practice and for oncology therapeutic development. These advancements, however, reveal new clinical questions regarding combinations and optimal sequencing of these agents in patients with BRAF mutant disease. We review the development of these agents, putative biomarkers, and resistance mechanisms relevant to their use, and possibilities for sequencing and combining these agents.

引用

页码：717 / 725

页数：9

共 71 条

[61] Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation [J].

van Elsas, A ;

Hurwitz, AA ;

Allison, JP .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (03) :355-366

[62] Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy [J].

van Elsas, A ;

Sutmuller, RPM ;

Hurwitz, AA ;

Ziskin, J ;

Villasenor, J ;

Medema, JP ;

Overwijk, W ;

Restifo, NP ;

Melief, CJM ;

Offringa, R ;

Allison, JP .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (04) :481-489

[63] Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling [J].

Wagle, Nikhil ;

Emery, Caroline ;

Berger, Michael F. ;

Davis, Matthew J. ;

Sawyer, Allison ;

Pochanard, Panisa ;

Kehoe, Sarah M. ;

Johannessen, Cory M. ;

MacConaill, Laura E. ;

Hahn, William C. ;

Meyerson, Matthew ;

Garraway, Levi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3085-3096

[64] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma [J].

Weber, Jeffrey ;

Thompson, John A. ;

Hamid, Omid ;

Minor, David ;

Amin, Asim ;

Ron, Ilan ;

Ridolfi, Ruggero ;

Assi, Hazem ;

Maraveyas, Anthony ;

Berman, David ;

Siegel, Jonathan ;

O'Day, Steven J. .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5591-5598

[65] Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [J].

Weisberg, E ;

Manley, PW ;

Breitenstein, W ;

Brüggen, J ;

Cowan-Jacob, SW ;

Ray, A ;

Huntly, B ;

Fabbro, D ;

Fendrich, G ;

Hall-Meyers, E ;

Kung, AL ;

Mestan, J ;

Daley, GQ ;

Callahan, L ;

Catley, L ;

Cavazza, C ;

Mohammed, A ;

Neuberg, D ;

Wright, RD ;

Gilliland, DG ;

Griffin, JD .

CANCER CELL, 2005, 7 (02) :129-141

[66] Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma [J].

Wilmott, James S. ;

Long, Georgina V. ;

Howle, Julie R. ;

Haydu, Lauren E. ;

Sharma, Raghwa N. ;

Thompson, John F. ;

Kefford, Richard F. ;

Hersey, Peter ;

Scolyer, Richard A. .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1386-1394

[67] Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors [J].

Wilson, Timothy R. ;

Fridlyand, Jane ;

Yan, Yibing ;

Penuel, Elicia ;

Burton, Luciana ;

Chan, Emily ;

Peng, Jing ;

Lin, Eva ;

Wang, Yulei ;

Sosman, Jeff ;

Ribas, Antoni ;

Li, Jiang ;

Moffat, John ;

Sutherlin, Daniel P. ;

Koeppen, Hartmut ;

Merchant, Mark ;

Neve, Richard ;

Settleman, Jeff .

NATURE, 2012, 487 (7408) :505-U1652

[68]

Wolchok Jedd D, 2010, Cancer Immun, V10, P9

[69] Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J].

Wolchok, Jedd D. ;

Neyns, Bart ;

Linette, Gerald ;

Negrier, Sylvie ;

Lutzky, Jose ;

Thomas, Luc ;

Waterfield, William ;

Schadendorf, Dirk ;

Smylie, Michael ;

Guthrie, Troy, Jr. ;

Grob, Jean-Jacques ;

Chesney, Jason ;

Chin, Kevin ;

Chen, Kun ;

Hoos, Axel ;

O'Day, Steven J. ;

Lebbe, Celeste .

LANCET ONCOLOGY, 2010, 11 (02) :155-164

[70] Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria [J].

Wolchok, Jedd D. ;

Hoos, Axel ;

O'Day, Steven ;

Weber, Jeffrey S. ;

Hamid, Omid ;

Lebbe, Celeste ;

Maio, Michele ;

Binder, Michael ;

Bohnsack, Oliver ;

Nichol, Geoffrey ;

Humphrey, Rachel ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2009, 15 (23) :7412-7420

← 1 2 3 4 5 6 7 8 →